CN Patent

CN121620369A — 用于治疗临床显著门静脉高压和失代偿期肝硬化的可溶性鸟苷酸环化酶激活剂

Assigned to Boehringer Ingelheim International GmbH · Expires 2026-03-06 · 0y expired

What this patent protects

本发明涉及用于使用可溶性鸟苷酸环化酶（sGC）激活剂预防临床显著门静脉高压（CSPH）和因非胆汁淤积型肝病导致的失代偿期肝硬化、减缓所述CSPH和所述失代偿期肝硬化的进展、延迟或治疗所述CSPH和所述失代偿期肝硬化的方法。

USPTO Abstract

本发明涉及用于使用可溶性鸟苷酸环化酶（sGC）激活剂预防临床显著门静脉高压（CSPH）和因非胆汁淤积型肝病导致的失代偿期肝硬化、减缓所述CSPH和所述失代偿期肝硬化的进展、延迟或治疗所述CSPH和所述失代偿期肝硬化的方法。

Drugs covered by this patent

Patent Metadata

Patent number
CN121620369A
Jurisdiction
CN
Classification
—
Expires
2026-03-06
Drug substance claim
No
Drug product claim
No
Assignee
Boehringer Ingelheim International GmbH
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.